Opinion
Video
Treatment Strategies for Patients with NMIBC: Importance of Risk Stratification
Author(s):
A panelist discusses how Non-muscle Invasive Bladder Cancer (NMIBC) treatment varies by risk stratification (low, intermediate, and high-risk), with BCG immunotherapy being standard for high-risk patients, while newer options like pembrolizumab and gene therapies are emerging for BCG-unresponsive cases, and treatment decisions between intravesical versus systemic therapy depend on risk level and previous treatment response.
Video Player is loading.
- Please share where the field of Non-muscle Invasive Bladder Cancer (NMIBC) is right now. Consider the following topics, which will be discussed in depth later on:
- Patient risk stratification
- Approved agents
- Investigational agents
- Please provide a brief overview of risk stratification for patients with NMIBC and treatment strategy for each group.
- What are the FDA-approved agents for treating patients with NMIBC, and what treatment options are available for BCG-naïve and BCG-unresponsive patients?
- How do intravesical therapies compare to intravenous therapies in this context?
Related Videos
Checkpoint Inhibitors for Treatment of NMIBC
Communication of Treatment Options for High-Risk NMIBC
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
BPH: The Patient Journey
How recombinant BCG could ease strain of supply issues
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
John Taylor, III, MD, on novel options in NMIBC
Related Content
